COSCA (Core Outcome Set for Cardiac Arrest) in Adults : An Advisory Statement From the International Liaison Committee on Resuscitation by COSCA collaborators et al.
Circulation. 2018;137:e783–e801. DOI: 10.1161/CIR.0000000000000562 May, 2018 e783
Kirstie Haywood, DPhil, 
BSc(Hons), PGCertHE*
Laura Whitehead, PhD, 
BMedSc(Hons)*
Vinay M. Nadkarni, MD, MS, 
FAHA, Co-Chair
Felix Achana, PhD
Stefanie Beesems, PhD
Bernd W. Böttiger, MD, ML
Anne Brooks
Maaret Castrén, MD, PhD
Marcus EH Ong, MBBS, MPH
Mary Fran Hazinski, MSN, 
RN, FAHA
Rudolph W. Koster, MD, PhD
Gisela Lilja, PhD
John Long
Koenraad G. Monsieurs, MD, 
PhD
Peter T. Morley, MBBS, FAHA
Laurie Morrison, MD, MSc
Graham Nichol, MD, MPH
Valentino Oriolo, RGN, MSc
Gustavo Saposnik, MD, MSc, 
FAHA
Michael Smyth, BSc (Hons), 
MSc
Ken Spearpoint, MSc,  
PGCertHE, BSc, RN
Barry Williams, LLB
Gavin D. Perkins, MB ChB, 
MMEd, MD, Co-Chair
On behalf of the COSCA  
Collaborators
© 2018 American Heart Association, Inc, 
and European Resuscitation Council.
ILCOR ADVISORY STATEMENT
COSCA (Core Outcome Set for Cardiac 
Arrest) in Adults 
An Advisory Statement From the International Liaison  
Committee on Resuscitation
Circulation
http://circ.ahajournals.org
ABSTRACT: Cardiac arrest effectiveness trials have traditionally reported 
outcomes that focus on survival. A lack of consistency in outcome 
reporting between trials limits the opportunities to pool results for meta-
analysis. The COSCA initiative (Core Outcome Set for Cardiac Arrest), 
a partnership between patients, their partners, clinicians, research 
scientists, and the International Liaison Committee on Resuscitation, 
sought to develop a consensus core outcome set for cardiac arrest 
for effectiveness trials. Core outcome sets are primarily intended for 
large, randomized clinical effectiveness trials (sometimes referred to 
as pragmatic trials or phase III/IV trials) rather than for pilot or efficacy 
studies. A systematic review of the literature combined with qualitative 
interviews among cardiac arrest survivors was used to generate a list of 
potential outcome domains. This list was prioritized through a Delphi 
process, which involved clinicians, patients, and their relatives/partners. 
An international advisory panel narrowed these down to 3 core 
domains by debate that led to consensus. The writing group refined 
recommendations for when these outcomes should be measured and 
further characterized relevant measurement tools. Consensus emerged 
that a core outcome set for reporting on effectiveness studies of cardiac 
arrest (COSCA) in adults should include survival, neurological function, 
and health-related quality of life. This should be reported as survival 
status and modified Rankin scale score at hospital discharge, at 30 days, 
or both. Health-related quality of life should be measured with ≥1 tools 
from Health Utilities Index version 3, Short-Form 36-Item Health Survey, 
and EuroQol 5D-5L at 90 days and at periodic intervals up to 1 year 
after cardiac arrest, if resources allow.
*Drs Haywood and Whitehead 
contributed equally to this article.
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ES Sudden cardiac arrest is one of the leading causes of death in industrialized nations. In the United States, ≈360 000 cardiac arrests are attended by 
emergency services each year, with only 10.6% of pa-
tients surviving to hospital discharge.1 Similar statistics 
apply across Europe and all other industrialized areas 
worldwide.2,3 However, survival rates vary widely both 
globally4 and regionally,5,6 with 4-fold or more region-
al variations reported. These low and variable survival 
rates highlight the importance of research that seeks to 
improve patient outcomes.
Randomized trials are important tools for evaluat-
ing the clinical efficacy and cost-effectiveness of inter-
ventions for in- and out-of-hospital cardiac arrest. Two 
broad types of trials have been described—efficacy and 
effectiveness. Efficacy (sometimes called explanatory) 
trials aim to test whether an intervention works un-
der optimal situations. Effectiveness (sometimes called 
pragmatic) trials are designed to assess how well an in-
tervention works in routine clinical practice.7 Ordinarily, 
efficacy trials focus on assessing the impact of an inter-
vention on a short-term outcome that is well correlated 
with long-term prognosis. Effectiveness trials seek to 
provide evidence of the longer-term health impact of an 
intervention.8,9 Evaluated outcomes can include clinical, 
clinician-reported, and patient-reported outcomes and 
resource use or economic impact. Clinical trials provide 
essential evidence of the relative benefit of an interven-
tion for stakeholders as diverse as clinicians, patients, 
and policy makers. Outcome selection is, therefore, an 
important aspect of trial design.9,10
Sometimes multiple trials might evaluate the same 
intervention in different settings. Reconciling disparate 
trial results can be challenging if each trial evaluated 
different outcomes at different time points. A system-
atic review of cardiac arrest trials published between 
2000 and 2012 included 61 publications that identi-
fied >160 different trial outcomes.11 No single outcome 
was reported across all trials. The majority of outcomes 
reflected short-term clinical and clinician-reported out-
comes, focusing on pathophysiological manifestations 
and process-based measures. Although survival was the 
most commonly reported outcome, 39 different defini-
tions of survival were used. Patient-reported outcomes12 
were rarely reported, although more recent trials have 
included these outcomes.13,14 This suggests that essen-
tial evidence of the impact of care from the survivors’ 
perspective is currently missing from clinical trials.
Adopting a consistent approach to outcome report-
ing for effectiveness trials has the potential to reduce 
heterogeneity in reporting, improve transparency in 
outcome selection, reduce reporting bias, and increase 
information available to pool for meta-analysis. Stan-
dardized reporting frameworks have been developed 
for reporting the findings of observational studies 
drawn from resuscitation registries.15,16 These frame-
works recommend 23 core data elements and 30 sup-
plementary elements across the 5 domains of system, 
dispatch, patient, process, and outcome.17 International 
guidelines exist for core outcomes to use in effective-
ness trials in patients with other conditions.18 Becker 
et al19 considered choices of primary outcomes across 
a range of resuscitation science studies but concluded 
that no single primary outcome was appropriate for 
all studies of cardiac arrest; however, no international 
guidelines exist to define a focused core outcome set 
(COS) for use in effectiveness trials in patients with car-
diac arrest.
The COMET initiative (Core Outcome Measures for 
Effectiveness Trials) promotes the development and 
application of agreed standardized sets of outcomes 
known as COS.20 A COS is defined as a small, standard-
ized group of outcomes that should be measured and 
reported, as a minimum, in all effectiveness trials for a 
specific health area.20,21 Effectiveness trials should aim 
to capture the COS as part of their a priori‒defined pri-
mary or secondary outcomes.
The COSCA initiative (Core Outcome Set for Cardiac 
Arrest), in collaboration with the International Liaison 
Committee on Resuscitation (ILCOR), sought to devel-
op a COS for cardiac arrest effectiveness trials covering 
both in- and out-of-hospital cardiac arrest. This consen-
sus article draws on the views and experiences of pa-
tients, the public, clinicians, policy makers, researchers, 
and the international perspectives represented through 
the ILCOR collaborative network. The process was in-
formed by systematic reviews of the literature, as well as 
qualitative research involving cardiac arrest survivors. A 
total of 168 participants used a Delphi process to draft 
a core cardiac arrest outcome set, and a 2-day meeting 
was convened to develop consensus recommendations.
METHODS
The available evidence associated with the development 
of COS18,20 and the websites of key COS development 
groups (COMET and OMERACT [Outcome Measures 
in Rheumatoid Arthritis Clinical Trials], later renamed 
Outcome Measures in Rheumatology) informed our 
approach. The project was registered with the COMET 
initiative.22 Ethical approval was obtained from the 
National Health Service Black Country Research Ethics 
Committee (13/WM/0464) to enable patients and their 
partners to participate.
Development of a COS involved 2 key steps: devel-
opment of a core domain set (ie, what to measure) fol-
lowed by identification of appropriate measurement tools 
(ie, how to measure).18,20 A core domain set was defined 
as referring to the minimum number of health domains 
(outcomes or aspects of health) that must be assessed. 
That is, it specifies what should be measured. Importantly, 
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this stage was driven by what is important and not how 
an outcome is assessed. The second stage involved the 
establishment of a core outcome measurement set, that 
is, the specific methods of assessment (ie, how to mea-
sure) for the domains identified in step 1. The selection 
of measurement tools was informed by an appraisal of 
measurement quality, relevance, and feasibility.
The OMERACT initiative suggests that a COS should 
seek to include at least 1 health domain across each of 
4 core areas of health (Figure 1): 3 core areas consider 
the impact of a health condition (ie, survival, life impact, 
economic impact/resource use), and the fourth core area 
reflects any pathophysiological manifestations associated 
with the condition.18 Several reviews11,23,24 suggest that 
these domains are relevant and encompass the large 
number of outcomes assessed in cardiac arrest trials.
To develop the consensus outcome criteria, a 4-stage 
approach was used, which consisted of the following 
steps, each of which is explained in detail: (1) stage 1: 
generation of an extensive list of potential outcomes 
across 4 core areas of health; (2) stage 2: an interna-
tional Delphi approach to refine and prioritize a list of 
potential outcomes; (3) stage 3: an international expert 
panel meeting; and (4) stage 4: synthesis of findings 
and recommendations for measurement tools.
Stage 1: Generation of an Extensive List 
of Potential Outcomes Across 4 Core 
Areas of Health
This stage was informed by a systematic review of the 
literature and qualitative interviews with cardiac arrest 
survivors and their partners. The systematic review fo-
cused on the identification of outcomes reported from 
randomized controlled trials that enrolled adults who 
had sustained a cardiac arrest.11 The findings from the 
systematic review were supplemented by conducting 
semistructured interviews with adult cardiac arrest sur-
vivors (and, if available, their partners) between 3 and 
12 months after discharge from the hospital after their 
cardiac arrest. Interviews were conducted, recorded, 
and transcribed with NVivo (QSR International, London, 
United Kingdom) by Dr Whitehead. Data were analyzed 
using interpretative phenomenological analysis, which 
seeks to capture the individual’s experience of a phe-
nomenon and how they understand their experiences.25 
Findings from the systematic review and qualitative re-
search were synthesized to produce an extensive list 
of potential outcomes. These were grouped under the 
OMERACT core area headings of survival, life impact, 
resource use/economic, and pathophysiological mani-
festations of cardiac arrest for consideration in stage 2.
Stage 2: International Delphi Approach 
to Refine and Prioritize List of Potential 
Outcomes
The list of potential outcomes identified during stage 
1 were placed into an online survey tool (SurveyMon-
key, Dublin, Ireland). Separate surveys were developed 
for healthcare professionals and patients/patient advo-
cates. The ILCOR network of 7 regional resuscitation 
councils was used to solicit the views of healthcare pro-
fessionals and patient and public advocates. Each ILCOR 
member (n=27) was asked to invite 6 healthcare pro-
fessionals and 3 patients to participate in the relevant 
surveys by E-mail. The outcomes were prioritized in 2 
rounds. Questions were structured to allow participants 
to rate the importance of each outcome at 5 different 
time points across the patient journey: during cardio-
pulmonary resuscitation (CPR), immediately after CPR, 
during hospitalization, at hospital discharge, and within 
Figure 1. OMERACT framework 2.0 modified for cardiac arrest. 
ICU indicates intensive care unit; OMERACT, Outcome Measures in Rheumatology; QOL, quality of life; and ROSC, return of 
spontaneous circulation. Reprinted from Boers et al.18 Copyright © 2014, The Authors. https://creativecommons.org/licenses/
by-nc-nd/3.0/. 
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the first year after the cardiac arrest. In the first round, 
survey participants were also given the opportunity to 
suggest additional outcomes they considered impor-
tant if they were not currently included in the survey. At 
the end of each round, outcomes rated as being of criti-
cal importance by >70% of respondents and rated as 
being of limited importance by <15% of respondents 
were advanced for additional consideration by the ex-
pert panel in stage 3. Similarly, those outcomes rated 
of limited importance by >70% of respondents and 
of critical importance by <15% of respondents were 
discarded. The findings from the first round were sum-
marized and presented for a second round of prioritiza-
tion. Any new suggestions were included in the sec-
ond round. The second round of prioritization differed 
by asking participants to rank outcomes according to 
importance. Outcomes that received strong support 
(>70% agreement) were also advanced for consider-
ation by the expert panel in stage 3. Outcomes that re-
ceived moderate support (60%–69% agreement) were 
also presented to the expert panel in stage 3.
Stage 3: International Expert Panel 
Meeting
The aim of the international expert panel was to con-
sider the shortlist of outcomes identified during stage 
2 and select a COS comprising 4 to 8 outcomes and 
make recommendations of measurement tools to cap-
ture those outcomes. A 2-day consensus meeting was 
convened in Prague, Czech Republic, in October 2015. 
A group of experts uninvolved in previous stages was 
purposefully selected to capture those involved in clini-
cal research (clinicians, clinical trialists, methodologists), 
experts in the use of measurement tools for cardiac ar-
rest, healthcare providers involved in treating patients 
with cardiac arrest (physicians, nurses, paramedics, al-
lied health professionals), and survivors of cardiac ar-
rests and patient advocates.
Before the meeting, the participants were sent a 
written summary of the outcome selection process de-
scribed above. At the start of the meeting, an over-
view of steps undertaken and findings from stages 1 
and 2 were presented. The shortlisted outcomes were 
presented in a matrix that covered the OMERACT core 
area headings of survival, life impact, resource use/eco-
nomic, and pathophysiological manifestations of car-
diac arrest during CPR, immediately after CPR, during 
hospitalization, at hospital discharge, and within the 
first year after the cardiac arrest. Initial presentations 
were followed by semistructured, small-group discus-
sions that covered the 4 core areas. Each core area was 
assigned a facilitator who supported 4 rounds of dis-
cussions on that topic. Each discussion group included 
a survivor of cardiac arrest or a patient advocate, as 
well as several researchers and clinicians who partici-
pated in small-group discussion across each core area. 
Each group nominated a recorder. The groups were 
tasked to consider the importance, relevance, accept-
ability, and feasibility of the short-listed outcomes as 
potential core outcomes for cardiac arrest effectiveness 
trials. The facilitator encouraged all group members 
to participate in discussions and shared key findings 
from each group with the next. This enabled consid-
eration of and building upon what other participants 
had discussed, facilitated the identification of issues of 
agreement and disagreement, and supported a flow of 
new ideas or key issues between groups. Thereafter, 
participants reconvened in a whole-group discussion 
session, in which facilitators and group recorders sum-
marized feedback from the small-group discussions, 
including areas of agreement and disagreement. The 
large-group discussion sought to collectively explore 
agreement and refine issues or concerns raised within 
each core area. At the end of the first day, expert panel 
members were invited to reflect on the day’s discus-
sions and then vote for up to 7 outcomes they believed 
should be included as core outcomes. Secure electronic 
votes were submitted by use of TurningPoint software 
and ResponseWare keypads (Turning Technologies, 
Youngstown, Ohio). The second day followed a similar 
model of large- and small-group discussions designed 
to allow further discussion and reflection on the op-
timal outcomes. A second round of voting was used 
to identify the final list of core outcomes. Proceedings 
were captured in the form of detailed written records 
from discussion groups, plenary sessions, and the out-
come of voting.
Stage 4: Synthesis of Findings and 
Recommendations for Measurement 
Tools
A writing group was appointed by ILCOR and endorsed 
by the American Heart Association Manuscript Over-
sight Committee after review for conflicts of interest. 
The charge to the group was to draw together and 
summarize the findings from stages 1 through 3. The 
group met by teleconference on 8 occasions and face-
to-face on 1 occasion.
The writing group reviewed and summarized the 
findings from stages 1 through 3 presented in this scien-
tific statement. The group undertook further work with 
the intention of making recommendations on relevant 
measurement tools for the outcome domains selected 
in stage 3. This was informed by considering existing 
measurement tools in cardiac arrest and other relevant 
diseases or injuries and discussing their quality, accept-
ability, and feasibility for application in clinical trials. Fi-
nal recommendations were reached through discussion 
and consensus among the writing group members.
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RESULTS
Stage 1: Generation of an Extensive List 
of Potential Outcomes Across 4 Core 
Areas (OMERACT Framework)
The systematic review identified 61 randomized tri-
als that reported 164 unique outcomes on 278 occa-
sions.11 The most frequently reported outcome was 
survival (85% of trials). This included return of spon-
taneous circulation (ROSC) before hospital admission, 
in the emergency department, or at any point during 
the resuscitation attempt. Survival was reported at 
various time points from emergency department ad-
mission, hospital discharge, and through to 3 years. 
There was a lack of consistency in definition and the 
time points at which survival was assessed, although 
most studies (90%) reported survival up to and in-
cluding hospital discharge. Pathophysiological out-
comes (eg, coronary perfusion pressure, arterial blood 
gas results) and life impact were frequently reported, 
although there was a lack of consistency in outcomes, 
measurement tools, and the timings of assessments. 
Process of care (eg, event timings), response to treat-
ment (eg, temperature achieved in targeted tempera-
ture management trials), quality of CPR, intervention 
success rates (eg, vascular access), and adverse out-
comes were reported in a quarter of studies. Writ-
ing group members identified trials published more 
recently that reported outcomes in the domain of life 
impact.13,14,26,27
Eleven interviews (8 patients, 3 partners) were con-
ducted to provide a detailed understanding of the lived 
experience of those surviving cardiac arrest. Five key 
themes were identified by patients that reflected the 
disruption to normality caused by cardiac arrest (sur-
vival, physical activities, emotional well-being, social 
well-being, and the impact on others; Table 1).
The findings from the systematic review and patient/
partner interviews were used to produce an extensive 
list of 53 potential outcomes, encompassing survival 
(5), life impact (24), economic impact and resource use 
(10), and pathophysiological manifestations (14), which 
were used in the stage 2 Delphi process.
Stage 2: International Delphi Approach 
to Refine and Prioritize Long List of 
Potential Outcomes
Ninety-nine healthcare professionals, 62 cardiac arrest 
survivors, and 7 relatives of cardiac arrest victims from 
15 countries participated in the Delphi survey. The clini-
cian group included 48 physicians, 12 nurses, 21 allied 
health professionals, 6 academics and 12 others. By the 
end of the 2 Delphi rounds, 25 outcome domains were 
prioritized (Figure 2).
Stage 3: International Expert Panel 
Meeting
A total of 23 expert panel members (including 2 sur-
vivors, 1 partner, and 1 patient advocate) participated 
from 11 countries (United Kingdom, the Netherlands, 
Finland, Germany, Belgium, Sweden, United States, 
Canada, Singapore, Australia, and New Zealand). The 
core outcome discussions and recommendations are 
summarized below.
Pathophysiological Manifestations
The expert panel considered circulatory function, re-
spiratory function, and brain function as potential 
core outcomes. There was general agreement that 
the assessment of these outcomes is of high impor-
tance during and immediately after cardiac arrest. 
They become less important once ROSC has been 
achieved. Consideration was given to the potential 
for pathophysiological measures to act as surrogate 
assessments for longer-term functional outcomes. For 
example, specific neuroimaging/electrophysiological 
tests might be a useful surrogate to reflect the im-
pact of a cardiac arrest on brain function.28 The panel 
considered these outcomes might be valuable during 
the validation of new interventions and advancing dis-
covery, for example, in efficacy trials; however, there 
was general agreement that the assessment of specific 
pathophysiological manifestations as core outcomes 
Table 1. Themes From Patient and Partner Interviews 
Relating to Disruption to Normality
Theme Examples
Survival Closeness to death
Gratitude to be alive
Impairment and 
impact on activities
Fatigue
Breathlessness
Vision
Muscle weakness
Pain (eg, fractured ribs)
Activities of daily living/increased dependence
Cognitive function
Emotional well-
being
Anxiety
Confidence
Depression
Self-esteem
Personality changes
Frustration
Social well-being 
and participation
Participation (role: job, voluntary, career)
Participation (leisure: hobbies, sports)
Participation (social activities)
Participation (family: relationships, intimacy)
Impact on others Increased work/care
Impact to participation—hobbies, work
Strain on relationships
Worry
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across the wide range of effectiveness trials in this 
field is of limited value.
The importance of reporting adverse events was dis-
cussed at length. There was general agreement that the 
reporting of adverse events should occur in accordance 
with Good Clinical Practice guidelines, which are rel-
evant to all clinical trials, rather than as a core outcome 
specific for cardiac arrest.
Although not introduced during the Delphi survey, 
participants discussed the importance of the quality of 
CPR (ie, CPR process) and its potential use as a core out-
come. Such measures could include compression rate, 
preshock pause duration, compression depth, or time 
to intervention. There was unanimous consensus that 
the processes of CPR are important contributors to out-
come after cardiac arrest. Participants recognized that 
CPR can be initiated or completed before a study inter-
vention is applied. Although CPR process could be an 
indicator of the quality of a resuscitation system of care 
or a potential modifier of the effect of a study interven-
tion, it was concluded that CPR process should not be 
a core outcome for effectiveness trials. This should not 
limit researchers from reporting CPR quality matrices 
to enable the assessment of associations between CPR 
performance and COS categories. Where such data are 
reported, use of standardized definitions29 and time in-
tervals could reduce variation in reporting.30
Survival
The expert panel discussed the relative importance of 
short-term survival, such as ROSC. The outcome was 
thought to be important in efficacy studies, which seek 
to advance discovery in this field, but contributed less 
toward understanding the longer-term aspects of sur-
vival.
Hospital-free survival (number of days alive and per-
manently outside a hospital in the first 30 days after 
cardiac arrest) was introduced during discussions. It was 
recently used in a large, pragmatic cardiac arrest trial31 
and offers potential statistical efficiencies over dichoto-
mous outcomes.32,33 Challenges can exist around the in-
terpretation of a composite outcome, which combines 
survival with length of hospital stay.
The panel concluded that longer-term survival (alive/
dead) should be the core survival outcome.
Life Impact
Patient/partner participants voiced a number of poten-
tially overlapping domains that can be affected after 
a cardiac arrest, which included cognition and con-
sciousness, physical symptoms, activities of daily living, 
health-related quality of life (HRQoL), emotional well-
being, family impact, participation, and fatigue. It was 
agreed that among the most common and significant 
impacts of cardiac arrest are potential changes to cog-
nition and neurological functioning. Other contribu-
tors to daily life, such as physical, social, and emotional 
changes after returning home, were discussed and con-
sidered important. To capture these important domains 
of health, a multidomain approach, including assessing 
an individual’s HRQoL after arrest, was favored.
The panel reached consensus that neurological func-
tion and HRQoL should be included as core outcomes.
Economic Evaluation
Although domains reflective of this core area were not 
prioritized by participants in the Delphi survey, the im-
portance attributed to this core area in the OMERACT 
initiative suggested that further discussion of the rela-
tive importance of this core area and possible domains 
was required. Group discussion highlighted the com-
plexities of capturing sufficient information to allow for 
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Circulatory function 
Respiratory function 
Renal function 
Brain function (neurologic markers)
Adverse events 
CPR process measures*
Survival Survival 
Life impact Consciousness and cognition 
Physical symptoms
Activities of daily living
Health-related quality of life
Emotional well-being 
Family impact 
Participation
Fatigue 
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resource use
Cost-effectiveness 
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Figure 2. Outcome domains presented for discussion  
at COSCA meeting. 
Circles indicate healthcare professionals and researchers; 
triangles indicate patients and partners. Gray fill indicates 
strong consensus (<70%); white fill indicates moderate sup-
port. Gray boxes were not rated or ranked on their impor-
tance. COSCA indicates Core Outcome Set for Cardiac Ar-
rest; and CPR, cardiopulmonary resuscitation. *Hospital-free 
survival and CPR process measures were introduced during 
expert panel meeting. 
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a full economic analysis of costs related to cardiac arrest. 
Although economic evaluation was judged to be impor-
tant, it was agreed that there was insufficient evidence 
to inform categorization currently. As a result, economic 
measures were not suggested as a core outcome.
Stage 4: Recommendations for 
Measurement Tools and Timing of 
Measurement
Survival
Survival to discharge and survival to 30 days were con-
sidered to be better indicators of patient recovery than 
shorter-term survival, such as survival to admission or 4 
to 6 hours after emergency department arrival. Discus-
sion highlighted international variation in the feasibility 
of collecting information on survival at discharge and 
survival at 30 days. Both time points have limitations: 
survival to discharge is limited by cultural differences 
(whether patients are discharged home to die or die 
predominantly in the hospital) and health system dif-
ferences (efficiency of discharge processes; whether 
long-term care is provided in the hospital or in home 
care settings). This can limit comparisons across differ-
ent health systems. Survival to specific intervals (eg, 30 
days) after arrest can avoid some of these limitations 
but in some settings requires consent, which, as noted 
elsewhere, can introduce bias through higher rates of 
loss to follow-up.
The writing group concluded that neither time point 
is perfect, and for consistency with the Utstein recom-
mendations,17 it was agreed either survival to hospital 
discharge or survival to 30 days would be acceptable to 
report as core outcomes. Researchers are encouraged 
to report both measures if feasible but should avoid 
reporting these as a composite outcome (survival to 
discharge or survival to 30 days) because this impairs 
pooling results in a meta-analysis.
Neurological Function
Five clinician-completed measures—the Cerebral Per-
formance Category (CPC),34 Structured CPC (assess-
ment by semistructured interview),35 CPC-Extended,36 
Glasgow Outcome Scale–Extended,37 and modified 
Rankin Scale (mRS)38—were considered. Moderate as-
sociations between the tools suggest that they measure 
related but not identical constructs.13,35,39–42 The CPC 
was not highly endorsed because of the lack of dis-
crimination between scores and the potential for ceil-
ing effects and overestimation of function.14,43–46 The 
CPC-Extended was considered to show good evidence 
of content validity, reliability, acceptability, and feasi-
bility, although its use in cardiac arrest survivors was 
limited at this time.36 The mRS and Glasgow Outcome 
Scale–Extended appear to provide improved granular-
ity.41,43 The mRS has been used more extensively in car-
diac arrest survivors13,41,47–55 than the Glasgow Outcome 
Scale–Extended44,56 or CPC-Extended.37
The writing group reached unanimous agreement 
that the mRS should be the outcome measurement 
tool of choice for neurological function. The mRS is 
a brief, clinician-completed, ordinal hierarchical rat-
ing scale used to determine a summary score of global 
disability57,58 after a neurological event or condition. 
The mRS captures impairment of physical and cogni-
tive abilities. Questions primarily focus on limitations 
in basic, instrumental, and more advanced daily activi-
ties and restrictions in ability to participate in normal 
social roles.58,59 There is evidence that it can discrimi-
nate between levels of mild and moderate disability.58 
It does not, however, provide detailed information of 
residual impairments and is unable to differentiate be-
tween whether effects are attributable to neurological 
or other sources of disability.58,60
How to Complete
mRS completion is preferably measured by direct inter-
view with the patient and any relevant caregiver, either 
face-to-face or by telephone (Table 2).57 Nonstandard-
ized interview administration requires ≈5 minutes.57 
When patients are unable to participate in interviews 
because of physical, language, or cognitive impairment, 
proxy completion—that is, completion by informants, 
such as family members, caregivers, or health profes-
sionals who know the patient well—can be considered. 
However, proxy completion without the involvement of 
the patient is associated with suboptimal levels of reli-
ability and validity.57,61 Although some studies suggest 
that indirect mRS completion from hospital records is 
less accurate,62 others suggest acceptable reliability af-
ter chart review by trained health professionals.36,39
Substantial inter-rater reliability of the mRS has been 
described,63 although this can be improved through 
Table 2. Core Outcomes, Time Point, and Preferred 
Methods for Collection
Outcome Time Point Preferred Method
Alternative 
Method
Survival 30 d or 
discharge
Ambulance/hospital 
records
Death registry
Neurological 
function 
(mRS)
30 d or 
discharge
Face-to-face interview 
by trained raters 
using mRS-9Q
Informant 
interview
Telephone 
assessment
Review of hospital 
records
Quality of life 90 d Face-to-face
(proxy completion 
where respondents 
are unable to 
participate)
Telephone 
interviews
Postal 
questionnaire
mRS indicates modified Rankin Scale; and mRS-9Q, 9-question mRS.
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digital training,63 use of a structured interview,59,64 or 
use of a web-based tool with 9 questions (mRS-9Q) and 
an mRS calculator.65 Use of trained raters and a struc-
tured approach to calculating the mRS score is recom-
mended. Raters should also be familiar with problems 
common after cardiac arrest.
Timing
The advantages and disadvantages outlined above for 
reporting survival status at discharge or at 30 days apply 
similarly to the reporting of favorable neurological func-
tion. Additional limitations of measuring neurological 
function at discharge are that the patient will not have 
been exposed to normal/their previous activities to allow 
accurate determination of the relevant mRS category. 
The time of discharge is also likely to be influenced by 
the degree and speed of recovery, with those having 
the greatest disabilities remaining in the hospital lon-
ger. Additional challenges imposed by assessing neuro-
logical function at 30 days include the requirement for 
the research team to specifically follow up with the pa-
tient, because unlike mortality, these data often are not 
tracked routinely. Incomplete follow-up confers a risk of 
introducing attrition bias. Whichever time point is select-
ed, the outcome should be reported as measured on the 
day of the assessment and not the best ever achieved.
The writing group accepted that there were ad-
vantages and disadvantages to both time points, and 
similar to our suggestion for assessing survival status, 
mRS score at discharge or 30 days was considered ac-
ceptable for reporting as a core outcome. Researchers 
can report both time points if feasible but should avoid 
reporting as a composite outcome (mRS score at dis-
charge or 30 days) because this impairs pooling results 
in a meta-analysis.
What to Report
Historically, cardiac arrest trials have dichotomized neu-
rological outcomes into favorable or unfavorable cat-
egories based on an mRS cutoff of ≤3.17,66,67 However, 
in stroke trials, an mRS score of ≤168 or ≤ 269 has been 
used to represent the cut off between favorable and 
unfavorable outcomes.
To enable consistent reporting and comparisons 
between articles, the writing group advised that the 
core outcome be presented as the number and per-
centage of patients in each of the 6 categories rather 
than solely being categorized into favorable and unfa-
vorable neurological outcome groups. This approach 
also provides greater granularity on clinically-relevant 
outcomes.70
To facilitate the transition to mRS as the core out-
come measurement tool and to support backward 
comparability, the writing group was also supportive 
of continued reporting of the CPC score over the next 
5 years, in addition to the mRS score. Useful informa-
tion for calculating the mRS score can be found on the 
Internet.71
The COSCA writing group suggested the use of the 
mRS version, where category 4 (moderate severe dis-
ability) includes dependency to attend to own bodily 
needs as separate from ability to walk unassisted (or 
instead of and). Outcome after cardiac arrest is less in-
fluenced by locomotor problems than after stroke, and 
this version will be more sensitive in identifying exten-
sive dependency related to severe cognitive impairment 
in a patient still able to walk. This version is available 
online.71 The scoring is as follows: 0=no symptoms; 
1=no significant disability—able to carry out all usual 
activities, despite some symptoms; 2=slight disability—
able to look after own affairs without assistance but 
unable to carry out all previous activities; 3=moderate 
disability—requires some help but able to walk unas-
sisted; 4=moderately severe disability—unable to at-
tend to own bodily needs without assistance and/or 
unable to walk unassisted; 5=severe disability—requires 
constant nursing care and attention, bedridden, incon-
tinent; and 6=dead.
Health-Related Quality of Life
The writing group spent considerable time deliberating 
which tools should be used to capture HRQoL after car-
diac arrest. Key considerations were the relevance or ac-
ceptability to cardiac arrest survivors, feasibility (eg, ease 
of use, information collection methods), the measure-
ment properties and their previous use in the cardiac 
arrest patient population, and cost. The writing group 
prioritized 6 generic measures of HRQoL for detailed 
consideration: 2 multi-item profile measures (the Short-
Form 36-Item Health Survey [SF-36]72 and Short-Form 
12-Item Health Survey [SF-12]73,74) and 4 preference-
based, multiattribute utility measures (the 15-dimen-
sion Quality of Life questionnaire [15-D],75 the Health 
Utilities Index version 3 [HUI3],76 and both the original 
and revised versions of the EuroQol [EQ-5D-3L77 and EQ-
5D-5L,78 respectively]). All preference-based measures 
include both descriptive systems and a utility index and 
hence could be used in cost-utility evaluations.79
The group was unable to reach consensus and rec-
ommend a single tool among these measures. Patient 
and public partners highlighted that none of the tools 
comprehensively captured their experiences of the af-
termath of a cardiac arrest. In online voting, the HUI3, 
followed by the SF-36 and EQ-5D-5L, received the most 
support (Table 3). The briefest measures are the EQ-5D-
5L (5 items) and HUI3 (8 items); the longest is the SF-
36v2 (36 items). Although all measures are intended to 
be measures of health status or HRQoL, the number of 
items and HRQoL coverage vary (Table 3). The HUI3 and 
EQ-5D-5L have a preponderance of items that relate 
to physical health, whereas items within the SF-36v2 
are equally distributed between physical and mental 
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Table 3. Summary and Item Content of Short-listed Generic HRQoL Measures (n=3)
PROM Details, 
Developer, 
Website, Cost 
(License), 
Completion 
Time
Conceptual Focus, 
Response Options/Recall 
Period, Completion 
Format, Language 
Versions
HRQoL Domains80
(Number of Items Per Domain)
How to Score
Symptom 
Status: 
Symptoms
Functional Status
General 
Health 
PerceptionPhysical Cognitive Psychological
Social/ 
Role
Preferences based (2)
  HUI3
  Website: www.
healthutilities.
com
  License for use 
per project; 
minimum fee 
$3000 (US)
  Completion 
time: ≈8 min  
for self-
completion; 
≈3 min for 
interview 
completion 
(not reported 
in cardiac arrest 
population)
  User guide: 
Available 
once HUI3 is 
purchased
  Country of 
origin: Canada
Preference-based, 
comprehensive system for 
measuring health status and 
HRQoL and for producing 
utility scores. Applicable for 
all people aged ≥5 y.
HUI3 classification system: 
describes the comprehensive 
health state of an individual 
across 8 attributes of general 
health (6 of 8 items reflect 
physical functional status)
Response options: Between 
4 and 6 descriptive response 
options (ability/disability)
Recall period: “Current” 
or “Usual”; “Usual” 
recommended for clinical 
studies. Choice of 1-, 2-, or 
4-wk recall available
Completion: Self, interview 
(in person; telephone), or 
proxy (proxy version available) 
supported
Language: 16 versions, 
including English, Chinese, 
Dutch, French, German, 
Italian, Japanese, Portuguese, 
Russian, Spanish, Swedish
Pain–
severity (1)
Ambulation: 
Ability 
to walk 
(distances)
Dexterity: 
Ability to use 
hands and 
fingers
Senses: 
Vision
Senses: 
Hearing
Speech: 
Ability to be 
understood 
(5)
Cognition: 
ability 
to solve 
day-to-day 
problems
(1)
Emotion: 
happiness and 
interest in life
(1)
  2 ways of presenting data:
1. HUI3 utility index: scored 
using single-attribute 
and multi-attribute utility 
functions
HUI-specific coding 
algorithms to support 
calculation of single-attribute 
Utility Score (Index)
Index range –0.36 to 1.00, 
where 1.00 is perfect health, 
0 is dead, and <0 is a health 
state worse than death
Population-based norms 
available
2. Multiattribute descriptive 
system (“Classification 
system”) reflects individual 
item scores
  EuroQol EQ-5D-
5L (EQ-5D-5L)
  Website: 
https://www.
euroqol.org/
  License: 
For use per 
project; free, 
but use must 
be registered 
on EuroQol 
website81
  Completion 
time: <5 min 
(not reported 
in cardiac arrest 
population)
  User guide: Free 
on website82
  Country of 
origin: Multiple
Standardized, preference-
based measure of health 
status for use in clinical and 
economic appraisal
EQ-5D descriptive system: 
5 items across “5 domains” 
(2 of 5 reflect physical 
functional status)
(EQ VAS: self-rated health 
on a 20-cm vertical visual 
analogue scale)
Response options: 5-level 
categorical response options 
per item (no problems [1] to 
extreme problems [5])
Completion of all items will 
produce a 5-digit number 
describing the respondent’s 
health state (but the 
numerals 1–5 have no 
inherent arithmetic properties 
and should not be used as a 
cardinal score)
Recall period: Today
Completion: Self, interview 
(in person, telephone), or 
proxy (2 proxy versions) 
supported83
Formats: PDA, pen and 
paper, proxy paper, tablet, 
telephone, web83
Language: >120 language 
versions: See website
Pain/
discomfort 
(1)
Mobility
Self-care (2)
– Anxiety/ 
depression (1)
Usual 
activities 
(including 
work, study, 
housework, 
and family 
or leisure 
activities)
(1)
– 2 ways of presenting data:
1. EQ-5D-5L Index value
EuroQol-specific coding 
algorithms to support 
calculation of Utility Score 
(Index): 
Crosswalk value sets from EQ-
5D-3L support calculation of 
EQ-5D-5L utility score. 
Index range –0.59 to 1.00, 
where 1.00 is perfect quality 
of life, 0 is death, and <0 is a 
health state worse than death. 
Country-specific value sets 
and population-based norms 
available. 
Report both measure of 
central tendency and a 
measure of dispersion, eg, 
mean and SD; median and 
percentiles
2. EQ-5D-5L descriptive system 
as a health profile: reflects 
individual item scores:
2.1 Report as the frequency 
or proportion of reported 
problems for each level for 
each dimension
2.2 Dichotomize into “No 
problems” (1) and “Problems” 
(2–5), report frequencies of 
reported problems
(Continued )
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health.79 Only the HUI3 includes items that measure 
cognition, speech, and dexterity, which are concerns 
relevant to cardiac arrest survivors. Only the SF-36v2 
includes an assessment of fatigue.
Preference-based utility scores can be calculated 
for HUI3, EQ-5D-5L, and SF-36v2 (in the form of the 
SF-6D86), which supports their use in cost-utility evalu-
ation. The SF-36v2 provides the most detailed profile 
score; that is, separate scores are calculated across the 8 
health domains, providing a more detailed assessment 
of health status than is otherwise afforded by the 2 sum-
mary scores. More limited descriptive profile scores can 
also be reported for both the HUI3 and EQ-5D across 
their 8 and 5 attributes, respectively. Normative popula-
tion data are available for all measures, which supports 
data interpretation and between-group comparisons. 
Estimates of meaningful change have been calculated 
for all measures after completion by the general popu-
lation and specific patient groups, which further sup-
ports data interpretation. License requests are required 
for all measures, but only the EQ-5D-5L is free to use.
A review of published evidence on the reliability and 
validity of these measures after completion by survivors 
of cardiac arrest demonstrated that the strongest evi-
dence was available for the HUI3, followed by the SF-
36v2.87 The EQ-5D-5L has not been evaluated in this 
population; however, evaluations in comparable popu-
lations suggest improved data quality and psychometric 
performance compared with the original EQ-5D-3L.78
In summary, multiple measures of HRQoL, including 
the SF-36v2, EQ-5D-5L, and HUI3, are acceptable for 
measurement of outcomes in trials enrolling patients 
with cardiac arrest. Each of these has strengths and 
weaknesses compared with other measures available. 
HUI3 has been applied frequently to patients with car-
diac arrest and directly measures cognition. The other 
measures are also acceptable.
How to Complete
Although all of the HRQoL measures discussed here 
were developed to be self-completed, all have been 
successfully administered by interview in person,40,42 
Profile measures (1)
  Short Form 
36-Item Health 
Survey, version 
2 (SF-36v2)
  Website: https://
campaign.
optum.com/
optum-
outcomes/
what-we-do/
health-surveys/
sf-36v2-health-
survey.html
  License: For 
use per project; 
minimum fee 
$US
  Survey license 
request: via 
website
  Completion 
time: Range 
5–30 min (not 
reported in 
cardiac arrest 
population)
  User guide: 
Available once 
SF-36v2 is 
purchased
  Country of 
origin: United 
States
Functional health and well-
being from the patient’s 
perspective: underpinned by 
8 health domains across both 
physical (4) and mental (4) 
aspects of health
Total 35 items plus 1 health 
transition item
Response options: Between 
3- and 6-level categorical 
response options per item
Recall period: Standard recall 
4 wk; acute recall 1 wk
Completion: Self, interview 
(in person; telephone), or 
proxy supported
Language: >170 language 
versions:
See website
The IQOLA project supported 
the development of 
conceptually equivalent 
and culturally appropriate 
translations84
Note: utility values
A preference-based utility 
index, the SF-6D, can be 
calculated after completion 
of the SF-36 to inform 
economic analyses85
Bodily pain 
(2)
Vitality: 
fatigue/
tiredness 
(2)
Physical 
functioning 
(10)
Role 
limitation (4)
– Mental health 
(5)
Role limitation 
(3)
Social 
functioning 
(2)
General 
health (5): 
perceived 
well-being
2 ways of presenting the 
data:
2.1 Eight-domain profile
2.2 Two component summary 
scales: PCS, MCS
Scoring requires SF-36–
specific algorithm.
Norm-based scoring: score 
transformed to 0–100 (mean 
50 [SD 10])
Population-based norms 
available
EQ VAS indicates EuroQol visual analogue scale; HRQoL, health-related quality of life; HUI3, Health Utilities Index 3; IQOLA, International Quality of Life Assessment; MCS, 
mental component summary; PCS, physical component summary; PDA, personal digital assistant; and PROM, patient-reported outcome measure.
Table 3. Continued
PROM Details, 
Developer, 
Website, Cost 
(License), 
Completion 
Time
Conceptual Focus, 
Response Options/Recall 
Period, Completion 
Format, Language 
Versions
HRQoL Domains80
(Number of Items Per Domain)
How to Score
Symptom 
Status: 
Symptoms
Functional Status
General 
Health 
PerceptionPhysical Cognitive Psychological
Social/ 
Role
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via the telephone,13,56,88,89 or both14 in the cardiac arrest 
population. Postal self-completion, although possible, 
has been used infrequently. However, the ability to 
self-complete a questionnaire after a cardiac arrest can 
be severely impaired by cognitive impairment (which 
can result in an overestimation of ability),90 fatigue, or 
general poor health. Although proxy ratings of nonob-
servable constructs such as emotional well-being and 
cognition can underestimate limitations,91,92 agreement 
is generally greater for more physical attributes.91,93,94 
Cronberg et al14 described interview-based proxy com-
pletion of the SF-36v2 with 8% of survivors at 6-month 
follow-up. Where possible, proxy completion by appro-
priate, well-informed assessors is suggested to ensure 
that the views of survivors who are unable to self-report 
are included in trials and the results do not underesti-
mate the impact of cardiac arrest on HRQoL.94
Timing
There was consensus that HRQoL should be measured 
after the patient’s discharge from the hospital. Patient 
recovery often continues to 6 months and beyond. 
Three-quarters of patients of a working age return 
to work after cardiac arrest at a median interval of 4 
months.95 The optimal time points and frequency of 
follow-up need to be considered in the context of study 
resources and overall study design. If sufficient resourc-
es are available to measure postdischarge outcomes, 
the group recommends, as a minimum, assessment at 
90 days. The group considered that this best balanced 
the trade-off between costs and other implications as-
sociated with longer-term follow-up with the positive 
effect of the value and stability of the data and is con-
sistent with the review of primary outcomes by Becker 
et al.19 However, it is recognized that health status can 
continue to change in the subsequent months and that 
capturing this change is important.41,95,96 Therefore, the 
group agreed that HRQoL could also be assessed at 180 
days or 1 year, or both. However, the longer duration of 
follow-up would be associated with increased logistic 
challenges and could be influenced by factors external 
to surviving a cardiac arrest.
DISCUSSION
The COSCA writing group identified that survival, neu-
rological function, and HRQoL should be reported as 
core outcomes in cardiac arrest effectiveness trials. Sur-
vival status should be reported at hospital discharge, 
at 30 days, or both. Neurological function (measured 
with the mRS) should be reported at hospital discharge, 
30 days, or both. HRQoL should be measured with ≥1 
tools from the HUI3, SF-36v2, or EQ-5D-5L at 90 days 
and at periodic intervals up to 1 year after cardiac ar-
rest, if resources allow.
COS are intended to enhance standardization of out-
comes that are reported for effectiveness trials. As such, 
future cardiac arrest effectiveness trials should include 
the core outcomes identified by COSCA as part of the 
a priori‒designated primary or secondary trial outcomes. 
The COS are intended to be complementary to other out-
come measures relevant to the particular intervention un-
der evaluation. The COS recommendations sit alongside, 
rather than replace, tools designed to enhance the quality 
and transparency of health research, such as SPIRIT (Stan-
dard Protocol Items: Recommendations for Interventional 
Trials)97 and CONSORT (Consolidated Standards of Re-
porting Trials)98 (Figure 3). Earlier phase trials will typically 
focus primarily on measures of efficacy, such as biomark-
ers, ROSC, or immediate survival, although selected core 
outcomes could also be considered.
Figure 3. Core outcome sets as 
part of Good Clinical Practice. 
Clinical trials are conducted within the 
overall framework of Good Clinical 
Practice, which supports clear and 
transparent reporting. Core outcome 
sets are suggested for inclusion as part 
of the a priori‒designated primary 
or secondary end points of effective-
ness trials. They enhance the quality 
and transparency of health research 
promoted by SPIRIT and CONSORT. 
CONSORT indicates Consolidated 
Standards of Reporting Trials; EQ-5D-
5L, 5-level EQ-5D; HUI3, Health Utilities 
Index version 3; mRS, modified Rankin 
scale; QoL, quality of life; SF-36, 36-
item Short Form Survey; and SPIRIT, 
Standard Protocol Items: Recommenda-
tions for Interventional Trials.
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Traditionally, outcome assessment of patients experi-
encing cardiac arrest has focused on survival rates and 
clinician-based assessments of outcome.11 However, 
the growth in patient-centered care and recognition of 
the importance of seeking to understand the impact 
of cardiac arrest from the perspective of the survivor 
demand a shift in the way that outcomes (in particular, 
over the longer term) are assessed in clinical trials. The 
use of well-developed questionnaires, which provide an 
assessment of how patients feel, function, and live their 
lives because of their health and health care, can pro-
vide essential patient-derived information to enhance 
outcome reporting in clinical trials.99 Such question-
naires or patient-reported outcome measures can be 
simply categorized as generic or specific (to a condi-
tion [eg, diabetes mellitus], a problem [eg, cognition], 
a function [eg, activities of daily life], or a population 
[eg, children]).
Generic measure of HRQoL, such as those short-listed 
in the COSCA recommendations (HUI3, SF-36v2, EQ-
5D-5L), includes multidimensional concepts (physical, 
social, emotional, and mental functioning) that provide 
a general assessment of HRQoL of relevance to patients 
and the general population, facilitating between-group 
comparisons and ensuring that the patient perspective 
is captured in clinical trials. Although the generic mea-
sures supported by COSCA start to move the focus to-
ward patient-centered outcomes, the current tools still 
fail to comprehensively capture the breadth of outcomes 
and experiences that matter most to cardiac arrest sur-
vivors.100–102 As a consequence, the impact of cardiac ar-
rest and associated health care might be incompletely 
assessed. Although a condition-specific measure for 
survivors of cardiac arrest does not currently exist, mea-
sures specific to problems of relevance to cardiac arrest 
survivors (eg, cognition, fatigue, anxiety, social participa-
tion) are available and have been used increasingly in 
this population.13,14,26,27,103–105 Although the COSCA rec-
ommendations do not currently include guidance for ≥1 
problems or function-specific measures, per good prac-
tice guidance for outcome assessment,91,92 where pos-
sible, we encourage their inclusion. Although not yet 
evaluated in the cardiac arrest population, the PROMIS 
initiative (Patient Reported Outcome Measures Informa-
tion System106) describes a range of fixed or dynamic 
(computer adaptive tests) self-report measures of physi-
cal, mental, and social health appropriate for use with 
the general population and those with chronic condi-
tions and hence suitable for comparing the burden of 
illness and treatment impact. The paucity of evidence to 
suggest which tools are best suited highlights the need 
for further research in this area.
Collecting HRQoL measures as an outcome of a 
clinical trial can be challenging and expensive. Some-
times, such data are missing from patients with the 
poorest outcomes, which can result in systematic 
bias, which cannot be ignored.107,108 To maximize the 
quality and timeliness of quality-of-life measures and 
reduce the risk of systematic bias caused by missing 
data, standardized administration and routine screen-
ing for avoidable missing data are advised.108–110 The 
approaches used and handling of missing data should 
be detailed in the study protocol and standard operat-
ing procedures.107,109
The writing group was cognizant of the balance that 
needs to be struck between the requirements of collect-
ing the core outcomes identified by the COSCA initia-
tive at a time of constrained research resources and the 
need to accelerate the pace of evidence-based change 
in resuscitation practices. The overall efficiency of the 
research pathway can be improved through a better 
understanding of the pathophysiology and effects of 
therapeutic interventions from animal and laboratory 
studies. By establishing proof of concept with evidence 
from early efficacy trials, internal pilot studies could re-
duce redundancy in effectiveness trials.111–113 Improving 
the efficiency of the conduction of trials114 and making 
use of registry data, where possible,115 could reduce 
costs and shorten the time to complete trials. The use of 
fixed dichotomous analysis of ordered categorical out-
comes is rarely the most statistically efficient approach 
and usually requires a larger sample size to demonstrate 
efficacy than other approaches.68 Alternative analytical 
approaches such as shift analysis and ordinal logistic re-
gression, used widely in stroke research,68,70 require fur-
ther evaluation in the cardiac arrest population. A better 
understanding of measurement properties of continu-
ous outcomes, such as hospital-free survival,32 might 
also aid reductions in sample size and trial costs.
CONCLUSIONS
Through a partnership between patients, partners, cli-
nicians, and researchers and endorsed by ILCOR, con-
sensus emerged that a COS for reporting on effective-
ness studies of cardiac arrest (COSCA) should include 
survival, neurological function, and HRQoL. To facilitate 
meaningful comparisons across studies over time, sur-
vival status and mRS at hospital discharge, 30 days, or 
both should be reported. HRQoL should be measured 
with ≥1 tools from the HUI3, SF-36v2, or EQ-5D-5L at 
90 days and at periodic intervals up to 1 year after car-
diac arrest, if resources allow.
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